Prostate Cancer

Zoladex significantly improves survival

Published in Cancer Weekly, September 3rd, 2002

New data published in the The Lancet show that the adjuvant use of Zoladex (goserelin acetate depot) with radiotherapy significantly prolongs overall survival, disease-free survival, and reduces disease progression in patients with locally advanced prostate cancer.

Patients treated with Zoladex adjuvant to radiotherapy showed a significant difference in overall survival compared with patients given radiotherapy alone (HR=3D0.51; 95% CI=3D0.36-0.73; p<0.0001). The 5-year survival estimates were 78% in the adjuvant therapy group and 62% in the radiotherapy alone group.

Patients treated with Zoladex adjuvant to radiotherapy also showed a...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-09-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry